Docket No.: 68004167-001001 App. No.: 10/787,497 (PATENT)

Amdt. dated June 20, 2007

Reply to Office Action mailed March 21, 2007

## I. AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions and listings.

## **Listing of Claims:**

Claim 1 (canceled).

Claim 2 (currently amended): A method of increasing angiogenesis, comprising administering to a patient an angiogenesis stimulating amount of a pharmaceutical composition containing a peptide or pharmaceutically acceptable salt thereof containing comprising the amino acid sequence LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES (LL-37) (SEQ ID NO: 1) and a pharmaceutically acceptable carrier.

Claims 3-20 (canceled).

- Claim 21 (New) The method of claim 2, wherein the peptide consists of SEO ID NO: 1.
- Claim 22 (New) A method of increasing angiogenesis, comprising administering to a patient a LL-37-receptor agonist in a pharmaceutically acceptable carrier in an amount sufficient to stimulate angiogenesis.
- Claim 23 (New) The method of claim 22, wherein the LL-37-receptor agonist comprises SEQ ID NO: 1.
- Claim 24 (New) The method of claim 22, wherein the LL-37-receptor agonist consists of SEQ ID NO: 1.
- Claim 25 (New) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating derivative of SEQ ID NO: 1.
- Claim 26 (New) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating peptidomimetic of SEQ ID NO: 1.
- Claim 27 (New) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating mutant of SEQ ID NO: 1.

App. No.: 10/787,497 Docket No.: 68004167-001001 Amdt, dated June 20, 2007 (PATENT)

Reply to Office Action mailed March 21, 2007

Claim 28 (New) The method of claim 22, wherein the LL-37-receptor agonist comprises an angiogenesis stimulating fragment of SEQ ID NO: 1.

- Claim 29 (New) A method of modulating angiogenesis, comprising administering to a patient a formyl peptide receptor-like 1 (FPRL1) agonist in a pharmaceutically acceptable carrier in an amount sufficient to stimulate angiogenesis or administering to a patient a FPRL1 antagonist in a pharmaceutically acceptable carrier in an amount sufficient to decrease angiogenesis.
- Claim 30 (New) The method of claim 29, wherein the FPRL1 agonist comprises SEQ ID NO: 1.
- Claim 31 (New) The method of claim 29, wherein the FPRL1 agonist consists of SEQ ID NO: 1.
- Claim 32 (New) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating derivative of SEQ ID NO: 1.
- Claim 33 (New) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating peptidomimetic of SEQ ID NO: 1.
- Claim 34 (New) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating mutant of SEQ ID NO: 1.
- Claim 35 (New) The method of claim 29, wherein the FPRL1 agonist comprises an angiogenesis stimulating fragment of SEQ ID NO: 1.
- Claim 36 (New) The method of claim 29, wherein the FPRL1 antagonist comprises an antibody that specifically binds to a peptide having SEQ ID NO: 1.
- Claim 37 (New) The method of claim 29, wherein the FPRL1 antagonist comprises an anti-FPRL1 antibody.
- Claim 38 (New) The method of claim 29, wherein the FPRL1 antagonist comprises a non-angiogenesis-stimulating mutant of SEQ ID NO: 1.
- Claim 39 (New) The method of claim 29, wherein the FPRL1 antagonist comprises a soluble form of FPRL1.